March 24, 2017
Alexion Pharmaceuticals said on March 22 that it has submitted an application in Japan for its terminal complement inhibitor Soliris (recombinant eculizumab) for an additional indication of generalized myasthenia gravis (gMG). The company is seeking approval for the drug’s use...read more